BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-129@catalystbrief.girapphe.com
DTSTAMP:20261117T181559Z
LAST-MODIFIED:20261117T181559Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Merck Sharp & Dohme LLC — Pembrolizumab [May 2027]
DESCRIPTION:Phase 3 primary completion: Study of Pembrolizumab With Concurr
 ent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapa
 rib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-0
 12).\nSource: https://clinicaltrials.gov/study/NCT04380636\nhttps://cataly
 stbrief.girapphe.com/e/129?lang=en\nNot investment advice. Dates may chang
 e.
URL:https://catalystbrief.girapphe.com/e/129?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
